Immunome
A US biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics.
In January 2023, US pharma major AbbVie revealed that it has agreed a back-loaded partnership and option accord with Immunome directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine.The company’s initial focus is on discovering and developing therapeutics in oncology internally and in collaboration with partners.
Latest Immunome News & Features
7 February 2024
9 January 2023
14 March 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze